You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: January 6, 2025

Details for Patent: 9,687,474


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 9,687,474
Title:Patch
Abstract: In a patch comprising a support layer and an adhesive agent layer, the adhesive agent layer comprises asenapine and/or a pharmaceutically acceptable salt thereof, isopropyl palmitate, and an adhesive base agent.
Inventor(s): Suzuki; Masayuki (Tsukuba, JP), Okutsu; Hiroaki (Tsukuba, JP), Yasukochi; Takashi (Tsukuba, JP), Takada; Yasunori (Tsukuba, JP)
Assignee: HISAMITSU PHARMACEUTICAL CO., INC. (Tosu-shi, JP)
Application Number:14/416,964
Patent Claim Types:
see list of patent claims
Compound;
Patent landscape, scope, and claims:

Understanding the Scope and Claims of United States Patent 9,687,474

Introduction

United States Patent 9,687,474, titled "Patch," is a utility patent that covers a specific type of transdermal patch. To delve into the details of this patent, it is crucial to analyze its scope, claims, and the broader patent landscape it operates within.

Patent Overview

The patent in question, US 9,687,474 B2, was granted for a patch comprising a support layer and an adhesive agent layer. The adhesive agent layer includes asenapine or a pharmaceutically acceptable salt thereof. Here is a brief overview of the key components:

  • Support Layer: This layer provides the structural base for the patch.
  • Adhesive Agent Layer: This layer contains asenapine, a medication used for treating certain psychiatric conditions, such as schizophrenia and bipolar disorder[4].

Scope of the Patent

The scope of a patent is defined by its claims, which outline the specific protections granted to the inventor.

Claims

The claims in a patent application are critical as they define the boundaries of the invention and the protection it receives. Here are some key points regarding the claims in US 9,687,474:

  • Independent Claims: These claims stand alone and define the invention without reference to other claims. In this patent, the independent claims focus on the composition and structure of the patch, including the specific components and their arrangement.
  • Dependent Claims: These claims refer back to and further limit the independent claims. They often provide additional details or variations of the invention. For example, dependent claims might specify different concentrations of asenapine or additional components in the adhesive layer[4].

Patent Eligibility and Subject Matter

To be patentable, an invention must meet the criteria outlined in Title 35 of the U.S. Code, which includes being novel, non-obvious, and useful.

Novelty

The invention must be new and not obvious to someone skilled in the relevant field. A prior art search, which involves reviewing existing patents and publications, is essential to ensure the invention has not been previously disclosed[5].

Non-Obviousness

The invention must be significantly different from existing technology and not obvious to someone with ordinary skill in the field. This is often a point of contention and requires careful analysis to determine if the invention offers a substantial improvement over prior art[5].

Utility

The invention must have a practical application and be useful. In the case of US 9,687,474, the patch is designed to deliver asenapine transdermally, providing a specific and practical use in the field of psychiatry[4].

Recent Guidance on Patent Eligibility

The 2024 USPTO guidance update on AI patent eligibility, while not directly applicable to this pharmaceutical patent, provides insights into how patent eligibility is determined. Key takeaways include:

  • Integration into Practical Application: Claims must integrate judicial exceptions (such as abstract ideas or natural phenomena) into a practical application to be considered patent-eligible. This principle can be applied broadly to ensure that any invention, including pharmaceutical patches, demonstrates a concrete technological improvement[1].

Inventorship and Patent Applications

Determining the true and only inventors is crucial for a patent application. In the United States, invention involves two steps: conception of the idea and reduction of the idea to practice. The inventors listed must have contributed to these steps[2].

Patent Filing Process

The patent application process involves several steps, including:

  • Provisional vs. Non-Provisional Applications: A provisional application allows for an early filing date with fewer formal requirements, but a non-provisional application must be filed within 12 months to comply with all statutory requirements[5].
  • Filing and Examination: The application is filed with the USPTO and undergoes a search and examination process to ensure the invention meets the criteria for patentability[5].

Patent Landscape

The patent landscape for pharmaceutical patches is competitive, with numerous patents covering various aspects of patch design, drug delivery systems, and specific medications.

  • Prior Art: Conducting a thorough prior art search is essential to ensure that the invention is novel and non-obvious. This involves reviewing existing patents, publications, and other relevant materials[5].
  • Competitor Patents: Understanding competitor patents helps in identifying gaps in the market and potential areas for innovation. This can also inform strategies for differentiation and improvement[5].

Examples and Case Law

While the patent in question is not related to AI, the principles of integrating abstract ideas into practical applications and demonstrating concrete technological improvements are relevant. For example:

  • AI-Related Patents: The 2024 USPTO guidance update includes examples where claims involving AI technologies are evaluated for patent eligibility. These examples illustrate how specifying real-world applications and demonstrating practical utility can make a claim patent-eligible[1].

Key Takeaways

  • Claims Define Scope: The claims in a patent application are crucial as they define the scope of protection.
  • Patent Eligibility: The invention must be novel, non-obvious, and useful.
  • Practical Application: Integrating judicial exceptions into practical applications is key to patent eligibility.
  • Inventorship: Correctly determining the true and only inventors is essential.
  • Patent Filing: Understanding the difference between provisional and non-provisional applications and the examination process is vital.

FAQs

  1. What is the main component of the adhesive agent layer in US 9,687,474?

    • The main component is asenapine or a pharmaceutically acceptable salt thereof.
  2. Why is it important to conduct a prior art search?

    • To ensure the invention is novel and not obvious, and to avoid potential infringement issues.
  3. What are the key criteria for patent eligibility?

    • The invention must be novel, non-obvious, and useful.
  4. How do dependent claims differ from independent claims?

    • Dependent claims refer back to and further limit the independent claims, often providing additional details or variations.
  5. What is the significance of integrating judicial exceptions into practical applications?

    • It ensures that the claimed invention offers a concrete technological improvement and meets the criteria for patent eligibility.

Sources

  1. Understanding the 2024 USPTO Guidance Update on AI Patent Eligibility - Mintz
  2. Determining Inventorship for US Patent Applications - Oregon State University
  3. Patent Claims and Patent Scope - SSRN
  4. US9687474B2 - Patch - Google Patents
  5. Patents | The Maryland People's Law Library - People's Law Library

More… ↓

⤷  Subscribe


Drugs Protected by US Patent 9,687,474

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Hisamitsu SECUADO asenapine SYSTEM;TRANSDERMAL 212268-001 Oct 11, 2019 RX Yes Yes 9,687,474 ⤷  Subscribe Y ⤷  Subscribe
Hisamitsu SECUADO asenapine SYSTEM;TRANSDERMAL 212268-002 Oct 11, 2019 RX Yes No 9,687,474 ⤷  Subscribe Y ⤷  Subscribe
Hisamitsu SECUADO asenapine SYSTEM;TRANSDERMAL 212268-003 Oct 11, 2019 RX Yes No 9,687,474 ⤷  Subscribe Y ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 9,687,474

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan2012-165793Jul 26, 2012
Japan2013-078583Apr 4, 2013
PCT Information
PCT FiledJuly 25, 2013PCT Application Number:PCT/JP2013/070196
PCT Publication Date:January 30, 2014PCT Publication Number: WO2014/017594

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.